Search review questions

Economic outcomes: cost‐effectiveness · people with psychosis‐induced aggression or agitation

Tranquillisation or asleep: sedation ‐ medium term ‐ +/vs haloperidol Number of participants sedated · people with psychosis‐induced aggression or agitation

Global state: no improvement ‐ +/vs haloperidol ‐ medium term As defined in each study · people with psychosis‐induced aggression or agitation

Global state: need for additional medication ‐ medium termNumber of participants requiring additional medication · people with psychosis‐induced aggression or agitation

Global state: need for additional medication Number of participants requiring additional medication · people with psychosis‐induced aggression or agitation

Adverse effects/events: extrapyramidal symptoms ‐ +/vs haloperidol ‐ medium term Number of instances of extrapyramidal symptoms · people with psychosis‐induced aggression or agitation

Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage · people with psychosis‐induced aggression or agitation

Economic outcomes: cost‐effectiveness · people with psychosis‐induced aggression or agitation

Tranquillisation or asleep: sedation ‐ medium term · people with psychosis‐induced aggression or agitation

Global state: no improvement ‐ medium term · people with psychosis‐induced aggression or agitation

Global state: need for additional medication ‐ medium term · people with psychosis‐induced aggression or agitation

Adverse effects/events: extrapyramidal symptoms ‐ medium term · people with psychosis‐induced aggression or agitation

Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage · people with psychosis‐induced aggression or agitation

Economic outcomes: cost‐effectiveness · people with psychosis‐induced aggression or agitation

Adverse effects/events: extrapyramidal symptoms ‐ medium termNumber of instances of extrapyramidal symptoms · people with psychosis‐induced aggression or agitation

Tranquillisation or asleep: sedation ‐ medium termNumber of participants sedated · people with psychosis‐induced aggression or agitation

Global state: no improvement ‐ medium termAs defined in each study · people with psychosis‐induced aggression or agitation

Global state: need for additional medication ‐ medium termNumber of participants requiring additional medication · people with psychosis‐induced aggression or agitation

Adverse effects/events: extrapyramidal symptoms ‐ medium termNumber of instances of extrapyramidal symptoms · people with psychosis‐induced aggression or agitation

Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage · people with psychosis‐induced aggression or agitation

Economic outcomes: cost‐effectiveness · people with psychosis‐induced aggression or agitation

Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage · people with psychosis‐induced aggression or agitation

Economic outcomes: cost‐effectiveness ‐ clinically important · people with psychosis‐induced aggression or agitation

Tranquillisation or asleep: sedation ‐ medium term vs haloperidol Number of participants sedated · people with psychosis‐induced aggression or agitation

Global state: no improvement ‐ vs haloperidol ‐ medium term As defined in each study · people with psychosis‐induced aggression or agitation

Global state: no improvement ‐ vs olanzapine ‐ medium term As defined in each study · people with psychosis‐induced aggression or agitation

Global state: No clinically important overall improvement (as rated by individual trials) ‐ medium term ( · People with schizophrenia and schizophrenia‐like disorders

Mental state: specific ‐ negative symptoms ‐ average endpoint score (SANS, high score = poor) medium term ( · People with schizophrenia and schizophrenia‐like disorders

Mental state: general ‐ average endpoint score (PANSS, high score = poor) ‐ medium term, ( · People with schizophrenia and schizophrenia‐like disorders

Mental state: General ‐ average endpoint score (BPRS, high score = poor) ‐ medium term ( · People with schizophrenia and schizophrenia‐like disorders

Functioning: general ‐ average endpoint score (GAF, high score = good) medium term ( · People with schizophrenia and schizophrenia‐like disorders

Functioning: social ‐ average endpoint score (SDSS, high score = poor) medium term, ( · People with schizophrenia and schizophrenia‐like disorders

Quality of life: general ‐ average endpoint score (GWB, high score = good) ‐ short term ( · People with schizophrenia and schizophrenia‐like disorders

Health service outcomes: 1. Readmission to hospital by 11 to 12 months · people with severe mental disorders

Health service outcomes: 3. Number of readmissions by 12 months · people with severe mental disorders

Health service outcomes: 4. Number with multiple readmissions by 12 months · people with severe mental disorders

Health service outcomes: 5. Days in community to first admission by 12 months · people with severe mental disorders

Participant level outcomes: 1. Mental state ‐ psychiatric symptoms at 12 months (BPRS) · people with severe mental disorders

Participant level outcomes: 3. Satisfaction with care: perceived coercion at 11 ‐ 12 months · people with severe mental disorders

Health service outcomes: 1. Readmission to hospital by 11 to 12 months · people with severe mental disorders

Health service outcomes: 2. Hospital bed‐days · people with severe mental disorders

Health service outcomes: 3. Number with multiple readmissions by 12 months · people with severe mental disorders

Participant level outcomes: 1. Global state: GAF at 12 months · people with severe mental disorders

Participant level outcomes: 2. Satisfaction with care: perceived coercion or leverage at 11 to 12 months · people with severe mental disorders

Health service outcomes: 4. Compliance with medication by 11 to 12 months · people with severe mental disorders

Participant level outcomes: 2. Social functioning: trouble with police by 11 to 12 months, at least 1 arrest · people with severe mental disorders

Participant level outcomes: 2. Social functioning: trouble with police by 11 to 12 months, ever arrested/picked up by police for violence against a person · people with severe mental disorders

Participant level outcomes: 3. Social functioning: homeless by 11 to 12 months · people with severe mental disorders

Participant level outcomes: 5. Quality of life: victimisation by 11 to 12 months · people with severe mental disorders

Participant level outcomes: 6. Satisfaction with care/adverse events: perceived coercion by 11 to 12 months · people with severe mental disorders